Koumiss Consumption Alleviates Symptoms of Patients with Chronic Atrophic Gastritis:A Possible Link to Modulation of Gut Microbiota  

作　　者：Chang Kun Li Qiang Chuan Hou Duolana Wuri Laga Hong Xin Liu Siqinbateer Bao Ying Sun Aoqi Lai-Yu Kwok He Ping Zhang Bilige Menghe 

机构地区：[1]Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Key Laboratory of Dairy Products Processing, Ministry of Agriculture, Inner Mongolia Agricultural University, Huhhot 010018, China [2]Inner Mongolia Xilin Gol League Mongolian Hospital, Nadam West Street, Xilin Gol League, 026000, China

出　　处：《Journal of Nutritional Oncology》2017年第1期36-51,共16页肿瘤营养学杂志（英文）

摘　　要：Intestinal dysbiosis is closely related to a variety of medical conditions,especially gastrointestinal diseases.The present study aimed to investigate the effects of koumiss on chronic atrophic gastritis(CAG)in an outpatient clinical trial(n=10;all female subjects aged 41-55;body mass index ranging from 19.5 to 25.8).Each patient consumed three servings of koumiss per day(i.e.250 ml daily before each of 3 meals)for a 60-day period.The improvement of patients'symptoms was monitored by comparing the total scores of symptoms before and after the treatment.Meanwhile,the changes in the patients’fecal microbiota composition and specific blood parameters were determined.After the 60-day koumiss administration,significant symptom improvements were observed,as evidenced by the reduction of the total symptoms score,and changes in blood platelet and cholesterol levels.The changes in patients’fecal microbiota composition were found.The patients’fecal microbiota fell into two distinct enterotypes,Bacteroides dorei/Bacteroides uniformis(BB-enterotype)and Prevotella copri(P-enterotype).Significant less Bacteroides uniformis was found in the BB-enterotype patient group,while significant more butyrate-producing bacteria(e.g.Eubacterium rectale and Faecalibacterium prausnitzii)were found in the P-enterotype patient group,following koumiss administration.After stopping koumiss consumption,the relative abundance of some biomarker taxa returned to the original level,suggesting that the gut microbiota modulatory effect was not permanent and that continuous koumiss administration was required to maintain the therapeutic effect.In conclusion,koumiss consumption could alleviate the symptoms of CAG patients.Our results may help understand the mechanism of koumiss in alleviating CAG disease symptoms,facilitating the development of such products with desired therapeutic functions.

关 键 词：KOUMISS Chronic ATROPHIC GASTRITIS GUT MICROBIOTA PacBio single molecule real-time sequencing technology Enterotype 

分 类 号：R573.32[医药卫生—消化系统]